EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pantoprazole and riluzole target H + /K + ‐ ATPases and pH ‐sensitive K + channels in pancreatic cancer cells

Ganga Deshar iD, Nynne M Christensen, Ivana Novak iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Ganga Deshar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Riluzole, Pantoprazole, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 7th Framework Programme, Seventh Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal cancer type. PDAC is characterized by fibrotic, hypoxic, and presumably acidic tumor microenvironment (TME). Acidic TME is an important player in tumor development, progression, aggressiveness, and chemoresistance. The dysregulation of ductal ion transporters/channels might contribute to extracellular pH (pH e ) acidification and PDAC progression. Our aim was to test whether H + /K + ‐ATPases and pH‐sensitive K + channels contribute to these processes and could be targeted by clinically approved drugs. We used human pancreatic cancer cells adapted to various pH e conditions and grown in monolayers and spheroids. First, we created cells expressing pHoran4 at the outer plasma membrane and showed that pantoprazole, the H + /K + ‐ATPase inhibitor, alkalinized pH e . Second, we used FluoVolt to monitor the membrane voltage ( V m ) and showed that riluzole hyperpolarized V m , most likely by opening of pH‐sensitive K + channels such as TREK‐1. Third, we show that pantoprazole and riluzole inhibited cell proliferation and viability of monolayers and spheroids of cancer cells adapted to various pH e conditions. Most importantly, combination of the two drugs had significantly larger inhibitory effects on PDAC cell survival. We propose that co‐targeting H + /K + ‐ATPases and pH‐sensitive K + channels by re‐purposing of pantoprazole and riluzole could provide novel acidosis‐targeted therapies of PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RiluzolePantoprazolePancreatic NeoplasmsCarcinoma, Pancreatic DuctalProton Pump InhibitorsH(+)-K(+)-Exchanging ATPaseHumansHydrogen-Ion ConcentrationCell Line, TumorTumor MicroenvironmentPotassium ChannelsSpheroids, Cellular

Stichwörter der Autor:innen

BL 1249K2P channelsPPIsTREK‐1extracellular pH sensorproton pump inhibitorsspheroidstumor microenvironment

Substanzen

RiluzolePantoprazoleProton Pump InhibitorsH(+)-K(+)-Exchanging ATPasePotassium Channels

Autor:innen und Institutionen

  • Department of Biology, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Ganga Deshar, Ivana Novak

Förderung

  • 7th Framework Programme
  • Seventh Framework Programme

Zitieren

APA

Deshar, G., Christensen, N. M., & Novak, I. (2024). Pantoprazole and riluzole target H + /K + ‐ ATPases and pH ‐sensitive K + channels in pancreatic cancer cells. International Journal of Cancer. https://doi.org/10.1002/ijc.35076

Vancouver

Deshar G, Christensen NM, Novak I. Pantoprazole and riluzole target H + /K + ‐ ATPases and pH ‐sensitive K + channels in pancreatic cancer cells. International Journal of Cancer. 2024. doi:10.1002/ijc.35076

BibTeX
@article{Deshar2024,
  author = {Deshar, Ganga and Christensen, Nynne M and Novak, Ivana},
  title = {Pantoprazole and riluzole target H + /K + ‐ ATPases and pH ‐sensitive K + channels in pancreatic cancer cells},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35076}
}
Kostenlos starten →